New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
16:03 EDTINFIInfinity Pharmaceuticals reports Q4 EPS ($1.15) , consensus (87c)
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
10:05 EDTINFIHigh option volume stocks
Subscribe for More Information
09:43 EDTINFIActive equity options trading
Active equity options trading according to Track Data: AAPL DG ABX AMZN FXCM LVS FFIV INFI SD
January 12, 2015
08:14 EDTINFIInfinity Pharmaceuticals sees reporting Dynamo data in 2H15
Infinity (INFI) anticipates that it will report top line data from DYNAMO, a Phase 2 study of duvelisib in patients with refractory indolent non-Hodgkin lymphoma, in the second half of 2015 following the completion of patient enrollment in the first half of the year. Infinity also expects to complete enrollment of DUO, a Phase 3 study of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia, in the second half of 2015. During the year, Infinity expects three company-sponsored clinical studies of duvelisib to be initiated, including the first clinical study of duvelisib in combination with venetoclax . Duvelisib is an investigational oral inhibitor of phosphoinositide-3-kinase -delta and PI3K-gamma being developed jointly with AbbVie (ABBV) in oncology.
08:13 EDTINFIInfinity Pharmaceuticals sees FY15 revenue $105M-$125M, consensus $96.45M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use